vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Cheche Group Inc. (CCG). Click either name above to swap in a different company.
AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $32.8M, roughly 1.4× Cheche Group Inc.). Cheche Group Inc. runs the higher net margin — 0.5% vs -19.9%, a 20.4% gap on every dollar of revenue.
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Cheche Group Inc. is a leading automotive digital service provider headquartered in China. It offers integrated solutions including auto insurance intermediary services, smart auto after-sales support, and connected vehicle technology products, serving individual car owners, auto dealerships, and insurance partners across domestic and select Southeast Asian markets.
ABCL vs CCG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $32.8M |
| Net Profit | $-8.9M | $153.6K |
| Gross Margin | — | 5.7% |
| Operating Margin | -63.7% | — |
| Net Margin | -19.9% | 0.5% |
| Revenue YoY | 788.4% | — |
| Net Profit YoY | 73.9% | — |
| EPS (diluted) | $-0.03 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $32.8M | ||
| Q4 25 | $44.9M | — | ||
| Q3 25 | $9.0M | — | ||
| Q2 25 | $17.1M | $26.0M | ||
| Q1 25 | $4.2M | — | ||
| Q4 24 | $5.0M | $18.6M | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $7.3M | $36.1M |
| Q1 26 | — | $153.6K | ||
| Q4 25 | $-8.9M | — | ||
| Q3 25 | $-57.1M | — | ||
| Q2 25 | $-34.7M | $-492.4K | ||
| Q1 25 | $-45.6M | — | ||
| Q4 24 | — | $-196.7K | ||
| Q3 24 | $-51.1M | — | ||
| Q2 24 | $-36.9M | $-7.6M |
| Q1 26 | — | 5.7% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 4.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 4.3% |
| Q1 26 | — | — | ||
| Q4 25 | -63.7% | — | ||
| Q3 25 | -851.8% | — | ||
| Q2 25 | -290.2% | -2.0% | ||
| Q1 25 | -1479.6% | — | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | -1439.4% | — | ||
| Q2 24 | -1276.2% | -4.7% |
| Q1 26 | — | 0.5% | ||
| Q4 25 | -19.9% | — | ||
| Q3 25 | -637.8% | — | ||
| Q2 25 | -203.3% | -1.9% | ||
| Q1 25 | -1077.2% | — | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | -785.4% | — | ||
| Q2 24 | -504.3% | -21.0% |
| Q1 26 | — | $0.00 | ||
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.19 | — | ||
| Q2 25 | $-0.12 | $-0.01 | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | — | $-0.00 | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $20.0M |
| Total DebtLower is stronger | — | $193.3K |
| Stockholders' EquityBook value | $966.9M | — |
| Total Assets | $1.4B | $203.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $20.0M | ||
| Q4 25 | $128.5M | — | ||
| Q3 25 | $83.2M | — | ||
| Q2 25 | $92.4M | $23.1M | ||
| Q1 25 | $159.3M | — | ||
| Q4 24 | $156.3M | $21.1M | ||
| Q3 24 | $126.6M | — | ||
| Q2 24 | $148.3M | $28.2M |
| Q1 26 | — | $193.3K | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $690.0K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $966.9M | — | ||
| Q3 25 | $964.0M | — | ||
| Q2 25 | $1.0B | $47.1M | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.1B | $49.1M | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | $48.6M |
| Q1 26 | — | $203.5M | ||
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | $177.3M | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.4B | $177.7M | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | $139.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | — |
| Free Cash FlowOCF − Capex | $-44.6M | — |
| FCF MarginFCF / Revenue | -99.4% | — |
| Capex IntensityCapex / Revenue | 21.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-34.7M | — | ||
| Q3 25 | $-52.6M | — | ||
| Q2 25 | $-32.4M | $-44.7M | ||
| Q1 25 | $-11.6M | — | ||
| Q4 24 | $-108.6M | $-15.8M | ||
| Q3 24 | $-28.9M | — | ||
| Q2 24 | $-30.0M | $-1.0K |
| Q1 26 | — | — | ||
| Q4 25 | $-44.6M | — | ||
| Q3 25 | $-61.5M | — | ||
| Q2 25 | $-45.8M | — | ||
| Q1 25 | $-22.2M | — | ||
| Q4 24 | $-187.0M | $-16.0M | ||
| Q3 24 | $-47.4M | — | ||
| Q2 24 | $-50.1M | $-1.1K |
| Q1 26 | — | — | ||
| Q4 25 | -99.4% | — | ||
| Q3 25 | -687.0% | — | ||
| Q2 25 | -267.9% | — | ||
| Q1 25 | -524.0% | — | ||
| Q4 24 | -3702.8% | -85.9% | ||
| Q3 24 | -728.4% | — | ||
| Q2 24 | -683.8% | -0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 21.9% | — | ||
| Q3 25 | 99.7% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 251.1% | — | ||
| Q4 24 | 1552.7% | 1.2% | ||
| Q3 24 | 284.6% | — | ||
| Q2 24 | 274.6% | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
